3oag
From Proteopedia
(Difference between revisions)
												
			
			| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| + | |||
| ==Design and optimization of new piperidines as renin inhibitors== | ==Design and optimization of new piperidines as renin inhibitors== | ||
| - | <StructureSection load='3oag' size='340' side='right' caption='[[3oag]], [[Resolution|resolution]] 2.30Å' scene=''> | + | <StructureSection load='3oag' size='340' side='right'caption='[[3oag]], [[Resolution|resolution]] 2.30Å' scene=''> | 
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[3oag]] is a 4 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[3oag]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OAG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3OAG FirstGlance]. <br> | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=LPQ:(3R,4S)-N-{2-CHLORO-5-[(CYCLOPROPYLAMINO)METHYL]BENZYL}-N-CYCLOPROPYL-4-{6-[2-(2,6-DICHLORO-4-METHYLPHENOXY)ETHOXY]PYRIDIN-3-YL}PIPERIDINE-3-CARBOXAMIDE'>LPQ</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | 
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=LPQ:(3R,4S)-N-{2-CHLORO-5-[(CYCLOPROPYLAMINO)METHYL]BENZYL}-N-CYCLOPROPYL-4-{6-[2-(2,6-DICHLORO-4-METHYLPHENOXY)ETHOXY]PYRIDIN-3-YL}PIPERIDINE-3-CARBOXAMIDE'>LPQ</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3oag FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3oag OCA], [https://pdbe.org/3oag PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3oag RCSB], [https://www.ebi.ac.uk/pdbsum/3oag PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3oag ProSAT]</span></td></tr> | |
| - | + | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
| </table> | </table> | ||
| == Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/RENI_HUMAN RENI_HUMAN] Defects in REN are a cause of renal tubular dysgenesis (RTD) [MIM:[https://omim.org/entry/267430 267430]. RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype).<ref>PMID:16116425</ref>   Defects in REN are the cause of familial juvenile hyperuricemic nephropathy type 2 (HNFJ2) [MIM:[https://omim.org/entry/613092 613092]. It is a renal disease characterized by juvenile onset of hyperuricemia, slowly progressive renal failure and anemia.<ref>PMID:19664745</ref>  | 
| == Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/RENI_HUMAN RENI_HUMAN] Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. | 
| <div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| == Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 21: | Line 20: | ||
| From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| </div> | </div> | ||
| + | <div class="pdbe-citations 3oag" style="background-color:#fffaf0;"></div> | ||
| ==See Also== | ==See Also== | ||
| Line 29: | Line 29: | ||
| </StructureSection> | </StructureSection> | ||
| [[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category:  | + | [[Category: Large Structures]] | 
| - | [[Category: Prade | + | [[Category: Prade L]] | 
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Design and optimization of new piperidines as renin inhibitors
| 
 | |||||||||||
